Programmed death-ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after archiving sustained virologic response for hepatitis C virus infection.

biomarker hepatocellular carcinoma pathology programmed death-ligand 1 sustained virologic response

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 14 12 2018
accepted: 24 05 2019
entrez: 20 8 2019
pubmed: 20 8 2019
medline: 20 8 2019
Statut: ppublish

Résumé

The aim of the present study was to study the pathological prognostic factor of initial hepatocellular carcinoma (HCC) after archiving sustained virologic response (SVR) for hepatitis C virus (HCV) infection. A single-center retrospective analysis was performed for patients who underwent hepatectomy between 2003 and 2017. We studied clinico-pathological findings of resected liver tissues in 35 patients with HCC after SVR treated by interferon (IFN group) and 13 patients with HCC after SVR treated by direct acting antivirals (DAA group). We also performed immunohistochemical staining using antibodies against programmed death-ligand 1 (PD-L1), cytokeratin 19, epithelial cell adhesion molecule (EpCAM) and regulator of G-protein signaling 5 (RGS5). PD-L1 positive HCC was observed in 6 cases of the IFN group and 4 cases of the DAA group. In the IFN group, in univariate analysis of recurrence free survival after surgery (RFS), the PD-L1 expression had a statistically significant impact (HR=6.01; P=0.02). In the multivariate analysis of RFS, PD-L1 expression significantly remained (HR=5.01; P=0.03). For both RFS and overall survival, Kaplan-Meier curves confirmed that patients with PD-L1 expression showed significantly worse prognosis (log-rank test P<0.01). Nuclear grade, RGS5 expression, and EpCAM expression were significantly higher in the PD-L1-positive HCC group compared with the PD-L1-negative HCC group (P<0.05). Therefore, PD-L1 expression may be an independent prognostic factor of surgically resected HCC after achieving SVR.

Identifiants

pubmed: 31423211
doi: 10.3892/ol.2019.10448
pii: OL-0-0-10448
pmc: PMC6607026
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1458-1466

Références

N Engl J Med. 2002 Sep 26;347(13):975-82
pubmed: 12324553
Cancer. 2004 Oct 1;101(7):1616-22
pubmed: 15378504
Hepatology. 1991 Nov;14(5):864-74
pubmed: 1718835
Dev Dyn. 2007 Aug;236(8):2258-67
pubmed: 17626278
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Liver Int. 2009 Jan;29(1):126-32
pubmed: 18492017
Intern Med. 2008;47(19):1637-43
pubmed: 18827409
Hepatology. 2009 Mar;49(3):729-38
pubmed: 19072828
Clin Cancer Res. 2009 Feb 1;15(3):971-9
pubmed: 19188168
Hepatology. 2013 Mar;57(3):964-73
pubmed: 22991257
Ann Intern Med. 2013 Mar 5;158(5 Pt 1):329-37
pubmed: 23460056
Hepatology. 2013 Oct;58(4):1253-62
pubmed: 23564522
J Surg Oncol. 2013 Sep;108(3):192-6
pubmed: 23868206
Lab Invest. 2014 Feb;94(2):192-207
pubmed: 24296877
Clin Gastroenterol Hepatol. 2014 Jul;12(7):1186-95
pubmed: 24321207
Hepatology. 2014 Jun;59(6):2083-91
pubmed: 24604476
Lancet Infect Dis. 2015 Jun;15(6):645-53
pubmed: 25863559
PLoS One. 2015 Jun 12;10(6):e0129053
pubmed: 26070204
Hepat Oncol. 2015;2(4):371-379
pubmed: 26617981
Hum Pathol. 2016 Apr;50:24-33
pubmed: 26997435
Hepatology. 2016 Dec;64(6):2038-2046
pubmed: 27359084
J Gastroenterol Hepatol. 2017 Jul;32(7):1387-1393
pubmed: 28008658
Hepatology. 2017 May;65(5):1438-1450
pubmed: 28027574
Gastroenterology. 2017 May;152(6):1383-1394
pubmed: 28163062
J Hepatol. 2017 Oct;67(4):727-738
pubmed: 28532995
Oncol Lett. 2018 Feb;15(2):1763-1770
pubmed: 29434872
Am J Pathol. 1993 Sep;143(3):738-52
pubmed: 8362973
Gastroenterol Clin Biol. 1997;21(11):869-79
pubmed: 9587539

Auteurs

Reiichiro Kondo (R)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Jun Akiba (J)

Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan.

Sachiko Ogasawara (S)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Osamu Nakashima (O)

Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan.

Yoshiki Naito (Y)

Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan.

Hironori Kusano (H)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Yutaro Mihara (Y)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Masahiko Tanigawa (M)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Hirohisa Yano (H)

Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Classifications MeSH